NeOnc Technologies Receives Pharma Tech Outlook’s Top Drug Delivery Platform Award for 2024
07. Oktober 2024 11:00 ET
|
NeOnc Technologies Holdings, Inc.
WESTLAKE VILLAGE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical-stage medical biotechnology company, has been recognized by Pharma Tech Outlook as the Top...
NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate
05. August 2024 11:00 ET
|
NeOnc Technologies Holdings, Inc.
NeOnc’s second concurrent Phase 2 clinical study seeks further safety and preliminary evidence of biological effects of its lead drug candidate, NEO100™, on certain cancers of the brain and central...
NeOnc Initiates Cohort 3 in Phase 1 Clinical Trial of NEO212™, a Patented Novel Hybrid Drug Designed to Deliver ‘Double Punch’ Against Malignant Brain Tumors
24. Juli 2024 11:15 ET
|
NeOnc Technologies Holdings, Inc.
NEO212™ completes initial two cohorts of Phase 1 study under FDA Investigative New Drug (IND).Study tests the safety of NeOnc’s patented novel drug, NEO212™, which is the bioconjugation of its leading...
NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation
16. Juli 2024 11:15 ET
|
NeOnc Technologies Holdings, Inc.
FDA approval reflects positive results from Phase I and preliminary results from Phase IIa study currently underway that demonstrate increased survivability rates in patients with the IDH1...
NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status
26. Juni 2024 16:39 ET
|
NeOnc Technologies Holdings, Inc.
New investment and debt conversion by new and existing investors sets company’s post-money valuation at approximately $220 million, up 214% from previous funding round.Financing supports further...
NeOnc Technologies Wins California Investment Forum’s Breakthrough Medical Technology Achievement Award
15. Mai 2024 11:00 ET
|
NeOnc Technologies Holdings, Inc.
LOS ANGELES, May 15, 2024 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage biopharmaceutical company, has received the Breakthrough Medical Technology Achievement Award from...
NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10
09. Mai 2024 17:30 ET
|
NeOnc Technologies Holdings, Inc.
LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage biopharmaceutical company, is proud to be presenting at the 2024 California Investment Forum (CIF),...
NeOnc Technologies Holdings Receives FDA Authorization to Proceed with Phase 1/2 Trials of NEO212 for Primary Brain Tumors and for Brain Metastasis in Combination with Standard of Care Therapy
27. Juni 2023 11:00 ET
|
NeOnc Technologies Holdings, Inc.
U.S. FDA authorizes NeOnc to initiate Phase 1/2 clinical trials of NEO212.Clinical trials to evaluate NEO212 as a single agent for patients with primary brain tumors or uncontrolled brain...
NeOnc Technologies Formalizes Exclusive Global IP Licensing Agreement with USC for Enhanced Method of Delivering Novel Pharma Therapeutics to the Brain
24. April 2023 11:00 ET
|
NeOnc Technologies Holdings, Inc.
LOS ANGELES, April 24, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage medical biotechnology company, has formally secured exclusive worldwide rights from the University...
NeOnc Technologies Appoints Sidra Medicine CEO and Forbes Top 100 Healthcare Leader, Dr. Iyabo Tinubu-Karch, to Scientific Advisory Board
18. April 2023 09:15 ET
|
NeOnc Technologies Holdings, Inc.
LOS ANGELES, April 18, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage medical biotechnology company, has appointed Dr. Iyabo Tinubu-Karch to its scientific advisory...